“After ten years of ups and downs, I feel that I and everyone at Beike are lucky.” Dr. Hu Xiang was gentle and elegant in front of the camera, and told reporters his entrepreneurial story. This July coincides with the 10th anniversary of the establishment of Beike Biotechnology. Over the past ten years, Beike has developed from an unknown small company into a representative enterprise in the field of cell therapy in China.
On August 8, Shenzhen TV Financial Channel“High-end Interview” column in this issue“Standing at the forefront of global cell therapy” A conversation with Dr. Hu Xiang, a leader in China’s stem cell and regenerative medicine industry and chairman of Shenzhen Beike Biotechnology Co., Ltd., to explore the wonderful story of how he gave up the superior conditions abroad to start a business in China, devoted himself to the most cutting-edge basic research on stem cells and immune cell clinical application research and technical services, and created many firsts in the field of biomedicine. Experience the extraordinary charm of an outstanding entrepreneur who has a strong sense of responsibility and mission and works tirelessly to keep China’s biomedicine at the forefront of the world.
During the interview, Dr. Hu Xiang reviewed his entrepreneurial journey and shared the development history of Beike Biotech, from seizing opportunities to develop and innovate to successfully creating the Beike Biotech brand, from advanced scientific research technology to clinical tools for clinically solving diseases, from cell therapy technology research and development to providing cell storage services and preparation technology services from different sources, allowing the audience to better understand Beike Biotech and himself. Dr. Hu said that Beike Biotech has developed into an important representative of Shenzhen’s cell therapy “innovation chain + industrial chain” and participated in the construction and layout of major infrastructure for the development of precision medicine and personalized cell therapy industry – “Shenzhen Comprehensive Cell Bank + Shenzhen Regional Cell Preparation Center”.
On the day of the interview with the “High-End Interview” column, Xinhua News Agency had just reported BMCMedicine, a major national 863 project during the 12th Five-Year Plan period, released a five-year multi-center, randomized, double-blind, placebo-controlled clinical study of umbilical cord mesenchymal stem cells in the treatment of acute myocardial infarction at 11 heart centers including Beike and the Navy General Hospital. The release of the research results also proved the correctness and scientificity of the “comprehensive cell bank + regional cell preparation center” cell therapy industry layout path from clinical practice. With the rapid development of cell therapy technology, clinical transformation efficiency is improving, and the quality of public health care will also be greatly improved.
“High-end Interview” is a financial interview column created by Shenzhen TV’s financial channel. The interviewees are all well-known entrepreneurs at home and abroad. They mainly focus on current social news hot spots and use the perspective of economic observation to rationally focus on financial hot spots and share the entrepreneurial stories and business wisdom of each entrepreneur.